Cerner Corporation Stock News

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.

Cerner Corp. (CERN) shares closed today at 1.7% below its 52 week high of $93.44, giving the company a market cap of $26B. The stock is currently down 1.7% year-to-date, up 15.3% over the past 12 months, and up 74.6% over the past five years. This week, the Dow Jones Industrial Average rose 4.3%, and the S&P 500 rose 5.5%. Trading Activity Trading volume this week was 4.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Information Technology industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -27.7% The company's stock price performance over the past 12 months beats the peer average by 74.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -359.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.

Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.

Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.